Loading market dashboard
Genetic Technologies Limited
GENEHealthcareNASDAQAU
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Labcorp joins a national CRC trial as exclusive genetic testing provider, expanding Invitae-based testing and supporting cancer research.
Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members Research will also assess the clinical impact of broader genetic testing in colorectal cancer care BURLINGTON, N.C., May 29, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (CRC).
TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an in vivo adeno-associated virus vector-based gene therapy for the treatment of biallelic OTOF variant-associated hearing loss. Otarmeni, formerly known as DB-OTO, previously received Orphan Designation from the EMA. If approved, Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union (EU).
Design Therapeutics Inc. (NASDAQ:DSGN) stock surged during the premarket session on Monday.
COLUMBUS, Ohio, May 18, 2026 /PRNewswire/ -- M/I Homes, Inc. (NYSE: MHO) today announced that Eugene D. Smith, formerly Senior Vice President and Director of Athletics at The Ohio State University and currently President of Gene Smith Consulting, LLC, was elected to the Company's Board of Directors at its 2026 Annual Meeting of Shareholders held on May 13, 2026.
Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the primary endpoint, and with longer follow-up, 42% achieved normal hearing that included whispers
BridgeBio Pharma, Inc. has surged 130% since last year, now trading at a $14.4bn market cap, driven by optimism around its pipeline and ATTR-CM drug Attruby. Attruby posted $362m in 2025 sales but faces stiff competition from Pfizer and Alnylam, with future generic threats and no 2026 revenue guidance provided. BBIO reported a 2025 net loss of $725m on $502m revenue, highlighting ongoing high R&D and SG&A spending as it invests in pipeline expansion.
Weight-loss responses to GLP-1 obesity drugs, and risks of side effects, may be linked to genetic variants, according to a study conducted by DNA-testing service 23AndMe.
PALO ALTO, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- 23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects.
Spider silk's extraordinary combination of strength, elasticity, toughness, biocompatible, biodegradable, and low weight, properties that outperform Kevlar
